Zhaoke Ophthalmology Limited (HKG:6622)

Market Cap	1.70B
Revenue (ttm)	38.74M
Net Income (ttm)	-304.97M
Shares Out	547.96M
EPS (ttm)	-0.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	706,500
Average Volume	1,140,443
Open	3.080
Previous Close	3.090
Day's Range	3.060 - 3.210
52-Week Range	1.200 - 4.600
Beta	1.23
RSI	39.67
Earnings Date	Nov 28, 2025

About Zhaoke Ophthalmology

Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, Hong Kong, and internationally. It develops various drugs that cover ophthalmic indications, including dry eye disease, myopia, presbyopia, wet age-related macular degeneration, diabetic macular edema, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 294
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6622

Financial Performance

In 2024, Zhaoke Ophthalmology's revenue was 69.32 million, an increase of 269.73% compared to the previous year's 18.75 million. Losses were -237.49 million, -38.32% less than in 2023.

Financial numbers in CNY